Find in Library

Gliomas are the most common intrinsic brain tumors in adults, and in accordance with their clinical behavior and patients’ outcome, they are graded by the World Health Organization (WHO) classification of brain tumors. One very interesting candidate for targeted tumor therapy may be epidermal growth factor receptor (<i>EGFR</i>) amplification. Here, we performed an integrated comparative analysis of <i>EGFR</i> amplification in 34 glioma samples using standard fluorescence in situ hybridization (FISH) and Illumina EPIC Infinium Methylation Bead Chip and correlated results with molecular glioma hallmarks. We found that the EPIC analysis showed the same power of detecting <i>EGFR</i> amplification compared with FISH. <i>EGFR</i> amplification was detectable in high-grade gliomas (25%). Moreover, <i>EGFR</i> amplification was found to be present solely in <i>IDH</i> wildtype gliomas (26%) and <i>TERT</i> mutated gliomas (27%), occurring independently of MGMT promoter methylation status and being mutually exclusive with 1p/19q codeletion (LOH). In summary, EPIC Bead Chip analysis is a reliable tool for detecting <i>EGFR</i> amplification and is comparable with the standard method FISH. <i>EGFR</i> amplification is a phenomenon of <i>IDH</i> wildtype <i>TERT</i> mutated high-grade gliomas.